Overview

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Status:
Terminated
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
Phase:
Phase 3
Details
Lead Sponsor:
CTI BioPharma
Treatments:
Antibodies
Pixantrone
Rituximab